Genentech said its blood clot treatment drug,...

Genentech said its blood clot treatment drug, tissue plasminogen activator or TPA, was approved for sale in West Germany. Genentech’s licensee, Boehringer Ingelheim International, has begun shipping the drug under the name of Actilyse. The drug, known as Activase in the United States, has already been approved for sale in six other countries. The FDA’s refusal to approve TPA for treatment of heart attack victims in the U.S. has been viewed as a significant setback for the South San Francisco biotechnology firm.